Media stories about Presbia (NASDAQ:LENS) have been trending somewhat positive on Saturday, Accern reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Presbia earned a daily sentiment score of 0.00 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 45.3690411495125 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Presbia stock traded down $0.16 on Friday, hitting $1.78. The stock had a trading volume of 862 shares, compared to its average volume of 8,542. Presbia has a twelve month low of $1.61 and a twelve month high of $7.14.
A number of brokerages have weighed in on LENS. HC Wainwright set a $6.00 price target on Presbia and gave the stock a “buy” rating in a research report on Tuesday, May 29th. Zacks Investment Research raised Presbia from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research report on Saturday, June 16th. Finally, ValuEngine raised Presbia from a “hold” rating to a “buy” rating in a research report on Thursday, July 5th.
Presbia Company Profile
Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, New Zealand, Italy, the Netherlands, Ireland, Canada, and Germany.
Read More: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with MarketBeat.com's FREE daily email newsletter.